Use of 0.1% chlorine dioxide to inhibit the formation of morning volatile sulphur compounds (VSC).
The aim of this study was to evaluate the VSC-inhibiting effect of a commercially available mouthrinse (0.1% chlorine dioxide) when compared to its placebo. A 2-step double blind, crossover, randomised study was conducted with 14 dental students with healthy periodontium, who refrained from any mechanical plaque and tongue coating control during two 4-day experimental periods. The subjects were instructed to rinse 3 times daily with the assigned product during each period. A 7-day washout interval was established. VSCs levels were measured by a sulphide monitor at the beginning (baseline) and at the end of each experimental period. Statistical analyses were performed using Wilcoxon's and Mann-Whitney's non-parametric tests. At baseline, intragroup analysis revealed that VSCs levels did not differ between groups (p > 0.05); at day 5, the use of the chlorine dioxide mouthrinse did not change the baseline VSCs scores in the control group (p > 0.05), while a 2-fold increase was observed with the use of the placebo mouthrinse (p < 0.05). Intergroup analysis showed a significant difference between the VSCs levels of the test and control groups (40.2 +/- 30.72 and 82.3 +/- 75.63 ppb, p < 0.001) at day 5. Within the limits of this study, the findings suggest that a mouthrinse containing chlorine dioxide can maintain VSCs at lower levels in the morning breath.
Peruzzo
Daiane Cristina
DC
Bahia Foundation for the Development of Sciences, Department of Prosthodontics and Periodontics, School of Dentistry, State University of Campinas, Av. Evandro Batista Vieira 775/13, Campinas, SP, Brazil, CEP 13098-390. daiaperuzzo@yahoo.com.br
Jandiroba
Priscila Fontoura Castelo Branco
PF
Nogueira Filho
Getulio da Rocha
Gda R
D000293:Adolescent; D000328:Adult; D000891:Anti-Infective Agents, Local / Q000627:therapeutic use*; D001419:Bacteria / Q000187:drug effects; D017606:Chlorine Compounds / Q000627:therapeutic use*; D018592:Cross-Over Studies; D003773:Dental Plaque / Q000517:prevention & control; D004311:Double-Blind Method; D004338:Drug Combinations; D005260:Female; D006209:Halitosis / Q000188:drug therapy* / Q000517:prevention & control; D006801:Humans; D008297:Male; D010087:Oxides / Q000627:therapeutic use*; D010919:Placebos; D013457:Sulfur Compounds / Q000037:antagonists & inhibitors*; D016896:Treatment Outcome
D000891:Anti-Infective Agents, Local; D017606:Chlorine Compounds; D004338:Drug Combinations; D010087:Oxides; D010919:Placebos; D013457:Sulfur Compounds; C025109:chlorine dioxide